Hormones and Cancer

, Volume 3, Issue 1–2, pp 37–43 | Cite as

Functional Characterization of a Genetic Polymorphism in the Promoter of the ESR2 Gene

  • Santosh Philips
  • Alexandra Richter
  • Steffi Oesterreich
  • James M. Rae
  • David A. Flockhart
  • Narayanan B. Perumal
  • Todd C. Skaar
Article

Abstract

The ESR2 gene encodes the estrogen receptor beta protein. Several studies have shown that genetic variants in the ESR2 gene are associated with a variety of clinical phenotypes. However, very little is known about the functional significance of ESR2 genetic variants. We used a bioinformatics approach to identify regions of the ESR2 promoter that is evolutionarily conserved across the genomes of several species. We resequenced 1.6 kb of the ESR2 gene which included 0.8 kb of the promoter, 0.3 kb of exon ON, and 0.5 kb of the following intron. We identified five single-nucleotide polymorphisms (SNPs) in the ESR2 promoter and one SNP in the intron. Phase analysis indicated that the SNPs likely exist in 11 different haplotypes. Three of the SNPs (rs8008187, rs3829768, rs35036378) were predicted to alter transcription factor binding sites in the ESR2 promoter. All three were detected only in African American subjects. The rs35036378 SNP was in the TATA box and was highly conserved across species. ESR2 promoter reporter assays in LNCaP and SKBR3 cell lines showed that the variant construct containing the rs35036378 SNP allele had approximately 50% less activity relative to the wild-type construct. We conclude that the rs35036378 SNP appears to cause a reduced promoter activity of the ESR2 gene.

Keywords

ESR2 SNPs TATA box Promoter polymorphism 

Notes

Acknowledgments

This research was supported by NIH-PGRN (5U01GM061373, D.A.F.), NIH-NIGMS (U01GM061373, 5K24RR020815), NIH-NCRR M01-RR000042 (University of Michigan), M01-RR020359 (Georgetown University), M01-RR00750 (Indiana University) and the Pennsylvania Department of Health, Commonwealth Universal Research Enhancement (C.U.R.E.) Program (SO). We would like to acknowledge the additional COBRA investigators, Daniel Hayes, N. Lynn Henry, Vered Stearns, and Anna Maria Storniolo, who were the clinical investigators on the tamoxifen trial from which some of the samples were used in this study.

Conflict of Interest

We declare no conflict of interest.

Supplementary material

12672_2011_86_MOESM1_ESM.doc (36 kb)
ESM. 1 (DOC 36 kb)

References

  1. 1.
    Jin Y, Hayes DF, Li L, Robarge JD, Skaar TC, Philips S, Nguyen A, Schott A, Hayden J, Lemler S, Storniolo AM, Flockhart DA, Stearns V (2008) Estrogen receptor genotypes influence hot flash prevalence and composite score before and after tamoxifen therapy. J Clin Oncol 26:5849–5854PubMedCrossRefGoogle Scholar
  2. 2.
    Ntukidem NI, Nguyen AT, Stearns V, Rehman M, Schott A, Skaar T, Jin Y, Blanche P, Li L, Lemler S, Hayden J, Krauss RM, Desta Z, Flockhart DA, Hayes DF (2008) Estrogen receptor genotypes, menopausal status, and the lipid effects of tamoxifen. Clin Pharmacol Ther 83:702–710PubMedCrossRefGoogle Scholar
  3. 3.
    Ashton KA, Proietto A, Otton G, Symonds I, McEvoy M, Attia J, Gilbert M, Hamann U, Scott RJ (2009) Estrogen receptor polymorphisms and the risk of endometrial cancer. BJOG 116:1053–1061PubMedCrossRefGoogle Scholar
  4. 4.
    Domingues-Montanari S, Subirana I, Tomas M, Marrugat J, Senti M (2008) Association between ESR2 genetic variants and risk of myocardial infarction. Clin Chem 54:1183–1189PubMedCrossRefGoogle Scholar
  5. 5.
    Pirskanen M, Hiltunen M, Mannermaa A, Helisalmi S, Lehtovirta M, Hanninen T, Soininen H (2005) Estrogen receptor beta gene variants are associated with increased risk of Alzheimer's disease in women. Eur J Hum Genet 13:1000–1006PubMedCrossRefGoogle Scholar
  6. 6.
    Yu KD, Rao NY, Chen AX, Fan L, Yang C, Shao ZM (2010) A systematic review of the relationship between polymorphic sites in the estrogen receptor-beta (ESR2) gene and breast cancer risk. Breast Cancer Res Treat 126(1):37–45CrossRefGoogle Scholar
  7. 7.
    Wang K, Dickson SP, Stolle CA, Krantz ID, Goldstein DB, Hakonarson H (2010) Interpretation of association signals and identification of causal variants from genome-wide association studies. Am J Hum Genet 86:730–742PubMedCrossRefGoogle Scholar
  8. 8.
    Dickson SP, Wang K, Krantz I, Hakonarson H, Goldstein DB (2010) Rare variants create synthetic genome-wide associations. PLoS Biol 8:e1000294PubMedCrossRefGoogle Scholar
  9. 9.
    Borges S, Desta Z, Jin Y, Faouzi A, Robarge JD, Philip S, Nguyen A, Stearns V, Hayes D, Rae JM, Skaar TC, Flockhart DA, Li L (2010) Composite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients. J Clin Pharmacol 50:450–458PubMedCrossRefGoogle Scholar
  10. 10.
    Stephens M, Donnelly P (2003) A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 73:1162–1169PubMedCrossRefGoogle Scholar
  11. 11.
    Stephens M, Smith NJ, Donnelly P (2001) A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 68:978–989PubMedCrossRefGoogle Scholar
  12. 12.
    Thompson JD, Higgins DG, Gibson TJ (1994) CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 22:4673–4680PubMedCrossRefGoogle Scholar
  13. 13.
    Frazer KA, Pachter L, Poliakov A, Rubin EM, Dubchak I (2004) VISTA: computational tools for comparative genomics. Nucleic Acids Res 32:W273–279PubMedCrossRefGoogle Scholar
  14. 14.
    Loots GG, Ovcharenko I, Pachter L, Dubchak I, Rubin EM (2002) rVista for comparative sequence-based discovery of functional transcription factor binding sites. Genome Res 12:832–839PubMedGoogle Scholar
  15. 15.
    Jin Y, Desta Z, Stearns V, Ward B, Ho H, Lee KH, Skaar T, Storniolo AM, Li L, Araba A, Blanchard R, Nguyen A, Ullmer L, Hayden J, Lemler S, Weinshilboum RM, Rae JM, Hayes DF, Flockhart DA (2005) CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 97:30–39PubMedCrossRefGoogle Scholar
  16. 16.
    Li LC, Yeh CC, Nojima D, Dahiya R (2000) Cloning and characterization of human estrogen receptor beta promoter. Biochem Biophys Res Commun 275:682–689PubMedCrossRefGoogle Scholar
  17. 17.
    Hirata S, Shoda T, Kato J, Hoshi K (2001) The multiple untranslated first exons system of the human estrogen receptor beta (ER beta) gene. J Steroid Biochem Mol Biol 78:33–40PubMedCrossRefGoogle Scholar
  18. 18.
    Smith L, Coleman LJ, Cummings M, Satheesha S, Shaw SO, Speirs V, Hughes TA (2010) Expression of oestrogen receptor beta isoforms is regulated by transcriptional and post-transcriptional mechanisms. Biochem J 429:283–290PubMedCrossRefGoogle Scholar
  19. 19.
    Ashworth JJ, Smyth JV, Pendleton N, Horan M, Payton A, Worthington J, Ollier WE, Ashcroft GS (2008) Polymorphisms spanning the 0 N exon and promoter of the estrogen receptor-beta (ERbeta) gene ESR2 are associated with venous ulceration. Clin Genet 73:55–61PubMedCrossRefGoogle Scholar
  20. 20.
    Zhu X, Leav I, Leung YK, Wu M, Liu Q, Gao Y, McNeal JE, Ho SM (2004) Dynamic regulation of estrogen receptor-beta expression by DNA methylation during prostate cancer development and metastasis. Am J Pathol 164:2003–2012PubMedCrossRefGoogle Scholar
  21. 21.
    Suzuki F, Akahira J, Miura I, Suzuki T, Ito K, Hayashi S, Sasano H, Yaegashi N (2008) Loss of estrogen receptor beta isoform expression and its correlation with aberrant DNA methylation of the 5'-untranslated region in human epithelial ovarian carcinoma. Cancer Sci 99:2365–2372PubMedCrossRefGoogle Scholar
  22. 22.
    Zhao C, Lam EW, Sunters A, Enmark E, De Bella MT, Coombes RC, Gustafsson JA, Dahlman-Wright K (2003) Expression of estrogen receptor beta isoforms in normal breast epithelial cells and breast cancer: regulation by methylation. Oncogene 22:7600–7606PubMedCrossRefGoogle Scholar
  23. 23.
    Fan X, Xu H, Warner M, Gustafsson JA (2010) ERbeta in CNS: new roles in development and function. Prog Brain Res 181:233–250PubMedCrossRefGoogle Scholar
  24. 24.
    Drummond AE, Fuller PJ (2010) The importance of ERbeta signalling in the ovary. J Endocrinol 205:15–23PubMedCrossRefGoogle Scholar
  25. 25.
    Ellem SJ, Risbridger GP (2009) The dual, opposing roles of estrogen in the prostate. Ann N Y Acad Sci 1155:174–186PubMedCrossRefGoogle Scholar
  26. 26.
    Couse JF, Korach KS (1999) Estrogen receptor null mice: what have we learned and where will they lead us? Endocr Rev 20:358–417PubMedCrossRefGoogle Scholar
  27. 27.
    Minutolo F, Macchia M, Katzenellenbogen BS, Katzenellenbogen JA (2009) Estrogen receptor beta ligands: recent advances and biomedical applications. Med Res Rev 31(3):364–442. doi: 10.1002/med.20186 CrossRefGoogle Scholar
  28. 28.
    Xue Q, Lin Z, Cheng YH, Huang CC, Marsh E, Yin P, Milad MP, Confino E, Reierstad S, Innes J, Bulun SE (2007) Promoter methylation regulates estrogen receptor 2 in human endometrium and endometriosis. Biol Reprod 77:681–687PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Santosh Philips
    • 1
    • 4
  • Alexandra Richter
    • 2
  • Steffi Oesterreich
    • 2
  • James M. Rae
    • 3
  • David A. Flockhart
    • 1
  • Narayanan B. Perumal
    • 4
  • Todd C. Skaar
    • 1
  1. 1.Department of MedicineDivision of Clinical Pharmacology, Indiana University School of MedicineIndianapolisUSA
  2. 2.Department of Pharmacology and Chemical BiologyUniversity of Pittsburgh Cancer InstitutePittsburghUSA
  3. 3.Department of Internal MedicineUniversity of MichiganAnn ArborUSA
  4. 4.Indiana University School of InformaticsIndianapolisUSA

Personalised recommendations